Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) rose 8% following an announcement that the U.S. Food and Drug Administration has cleared the company's Tandem Mobi insulin pump to function as a tubeless automated insulin delivery system with up to seven days of wear.
The clearance establishes the Tandem Mobi as the first tubeless automated insulin delivery system authorized for extended wear. Rather than requiring a new pump, the change is enabled through a new tubeless cartridge and infusion set that convert the existing Mobi hardware into a tubeless configuration while preserving the pump's Control-IQ+ advanced hybrid closed-loop technology.
Under the approval, the Mobi will be cleared for use both as a tubeless device and with a tubed infusion set, giving users a choice in how they wear the system. The automated delivery system relies on continuous glucose monitor sensor values to forecast glucose trends 30 minutes ahead and automatically modify insulin delivery based on those predictions.
Tandem has scheduled a full commercial launch in the United States for the new tubeless cartridge and infusion set in the first half of 2027. The company said that customers who already own a Mobi pump that remains under warranty will not need to obtain a new device, because current hardware is compatible with the new tubeless components.
The tubeless infusion sets and cartridges will be sold exclusively through pharmacy channels to customers who have pharmacy benefits. The company estimates that pharmacy coverage currently reaches roughly 50% of insured lives in the United States and noted that it expects coverage to expand ahead of the launch and during 2027.
The Tandem Mobi system includes a 200-unit cartridge and offers features such as inductive charging, water resistance, the ability to receive remote software updates, and wireless uploads of pump and therapy data to the cloud-based Tandem Source platform.
Context and implications
The FDA clearance converts an existing tubed hybrid closed-loop pump into a tubeless automated delivery option through modular components, maintaining the underlying Control-IQ+ algorithm and hardware compatibility for in-warranty devices. Distribution limited to pharmacy channels and the current estimate that roughly half of insured lives are covered through pharmacy benefits are central to access and uptake ahead of the commercial rollout.